Potent and selective inhibitor of PI 3-kinase β
values are 0.69, 13.6, 47.8 and 136 nM for PI 3-Kβ
, PI 3-Kδ
, PI 3-Kγ
and PI 3-Kα
, respectively). Selectively inhibits in vivo
growth of the PTEN-deficient tumor xenografts HCC70 and PC3. Also exhibits antithrombotic activity.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of AstraZeneca UK Ltd.
Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.
Nylander et al.
Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.
Ni et al.
Cancer Discov., 2012;2:425